First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas

Pharmacology in the Era of Targeted Therapies: The Case of PI3K Inhibitors

(2016) E. Toska et al.   CLINICAL CANCER RESEARCH

Strategically Timing Inhibition of Phosphatidylinositol 3-Kinase to Maximize Therapeutic Index in Estrogen Receptor Alpha-Positive, PIK3CA-Mutant Breast Cancer

(2016) W. Yang et al.   CLINICAL CANCER RESEARCH

American Society for Clinical Pharmacology and Therapeutics

(2016)   CLINICAL PHARMACOLOGY & THERAPEUTICS

Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3K  and PI3K , Demonstrates Treatment Strategies for PIK3CA-Dependent Breast Cancers

(2016) K. Hudson et al.   MOLECULAR CANCER THERAPEUTICS

Phase I Trial of the Pan-PI3K Inhibitor Pilaralisib (SAR245408/XL147) in Patients with Chronic Lymphocytic Leukemia (CLL) or Relapsed/Refractory Lymphoma

(2015) J. R. Brown et al.   CLINICAL CANCER RESEARCH

First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer

(2015) G. I. Shapiro et al.   CLINICAL CANCER RESEARCH

Phase I Dose-Escalation Study of Pilaralisib (SAR245408, XL147), a Pan-Class I PI3K Inhibitor, in Combination With Erlotinib in Patients With Solid Tumors

(2015) J.-C. Soria et al.   ONCOLOGIST

Inhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth

(2015) Melanie Sweetlove et al.   Frontiers in Oncology

Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase- , as therapy for previously treated indolent non-Hodgkin lymphoma

(2014) I. W. Flinn et al.   BLOOD

First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Pan-Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors

(2014) D. Sarker et al.   CLINICAL CANCER RESEARCH

Targeting PI3K/mTOR Overcomes Resistance to HER2-Targeted Therapy Independent of Feedback Activation of AKT

(2014) N. A. O'Brien et al.   CLINICAL CANCER RESEARCH

Interim 18F-FDG PET SUVmax Reduction Is Superior to Visual Analysis in Predicting Outcome Early in Hodgkin Lymphoma Patients

(2014) C. Rossi et al.   JOURNAL OF NUCLEAR MEDICINE

PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma

(2014) Ajay K. Gopal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rapid Induction of Apoptosis by PI3K Inhibitors Is Dependent upon Their Transient Inhibition of RAS-ERK Signaling

(2014) M. Will et al.   Cancer Discovery

Metabolic Burden Measured by ¹⁸F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Is a Prognostic Factor in Patients with Small Cell Lung Cancer

(2014) Mi-Hyun Kim et al.   Cancer Research and Treatment

Oral and intravenously administered mTOR inhibitors for metastatic renal cell carcinoma: Pharmacokinetic considerations and clinical implications

(2013) Romano Danesi et al.   CANCER TREATMENT REVIEWS

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors

(2013) G. I. Shapiro et al.   CLINICAL CANCER RESEARCH

BAY 80-6946 Is a Highly Selective Intravenous PI3K Inhibitor with Potent p110α and p110δ Activities in Tumor Cell Lines and Xenograft Models

(2013) Ningshu Liu et al.   MOLECULAR CANCER THERAPEUTICS

A novel selective small-molecule PI3K inhibitor is effective against human multiple myeloma in vitro and in vivo

(2013) J Glauer et al.   Blood Cancer Journal

Management of Metabolic Effects Associated With Anticancer Agents Targeting the PI3K-Akt-mTOR Pathway

(2012) Naifa L. Busaidy et al.   JOURNAL OF CLINICAL ONCOLOGY

First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors

(2011) Timothy A. Yap et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors

(2011) Johanna C. Bendell et al.   JOURNAL OF CLINICAL ONCOLOGY

Regulation of arterial blood pressure by Akt1-dependent vascular relaxation

(2011) Jung Min Ha et al.   JOURNAL OF MOLECULAR MEDICINE-JMM

Mammalian target of rapamycin: Biological function and target for novel anticancer agents

(2010) E. B. Borders et al.   AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY

Insulin says NO to cardiovascular disease

(2010) Q. Yu et al.   CARDIOVASCULAR RESEARCH

Activity of any class IA PI3K isoform can sustain cell proliferation and survival

(2010) L. C. Foukas et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Contribution of Insulin and Akt1 Signaling to Endothelial Nitric Oxide Synthase in the Regulation of Endothelial Function and Blood Pressure

(2009) J. David Symons et al.   CIRCULATION RESEARCH

Take your PIK: phosphatidylinositol 3-kinase inhibitors race through the clinic and toward cancer therapy

(2009) N. T. Ihle et al.   MOLECULAR CANCER THERAPEUTICS

Dose- and Schedule-Dependent Inhibition of the Mammalian Target of Rapamycin Pathway With Everolimus: A Phase I Tumor Pharmacodynamic Study in Patients With Advanced Solid Tumors

(2008) Josep Tabernero et al.   JOURNAL OF CLINICAL ONCOLOGY

PI3K pathway alterations in cancer: variations on a theme

(2008) T L Yuan et al.   ONCOGENE